CBX2 Promotes Cervical Cancer Cell Proliferation and Resistance to DNA-damaging Treatment Via Maintaining Cancer Stemness

Overview

Journal J Biol Chem

Date 2025 Jan 10

PMID 39793896

Authors

Wenhan Li

Ru Shi

Yumei Gao

Xiaoman Wang

Tiantian Shen

Xiaoli Liu

Qiulei Wu

Xiaohan Xu

Zanhong Wang

Shi Du

Si Sun

Lu Yang

Jing Cai

Lin Liu

Affiliations

Soon will be listed here.

Abstract

Cervical cancer is the fourth most common malignancy and the fourth leading cause of cancer-related death among women. Advanced stages and resistance to treatment in cervical cancer induce cancer-related deaths. Although epigenetics has been known to play a vital role in tumor progression and resistance, the function of epigenetic regulators in cervical cancer is an area of investigation. In this study, we focused on an epigenetic regulator, polycomb repressor complex 1 in cervical cancer. Through bioinformatics analysis and immunochemistry, we subsequently identified chromobox 2CBX2), the deregulated subunit of polycomb repressor complex 1, which is upregulated in cervical cancer and associated with poor prognosis and unfavorable clinicopathological characteristics. We provided functional evidence demonstrating that CBX2 promoted cervical cancer cell proliferation. Furthermore, CBX2 exhibited an antiapoptotic effect, which induced resistance to cisplatin and ionizing radiation in cervical cancer cells. Moreover, CBX2 was involved in maintaining cancer stemness. These findings suggest that CBX2 plays an important role in cervical cancer progression and resistance to treatment, and may serve as a potential biomarker for prognosis and resistance as well as a potential therapeutic target.

References

Clermont P, Crea F, Chiang Y, Lin D, Zhang A, Wang J . Identification of the epigenetic reader CBX2 as a potential drug target in advanced prostate cancer. Clin Epigenetics. 2016; 8:16. PMC: 4751702. DOI: 10.1186/s13148-016-0182-9. View

Sproll P, Eid W, Biason-Lauber A . CBX2-dependent transcriptional landscape: implications for human sex development and its defects. Sci Rep. 2019; 9(1):16552. PMC: 6851130. DOI: 10.1038/s41598-019-53006-7. View

Wang L, Ren B, Zhuang H, Zhong Y, Nan Y . CBX2 Induces Glioma Cell Proliferation and Invasion Through the Akt/PI3K Pathway. Technol Cancer Res Treat. 2021; 20:15330338211045831. PMC: 8558802. DOI: 10.1177/15330338211045831. View

Mao J, Tian Y, Wang C, Jiang K, Li R, Yao Y . CBX2 Regulates Proliferation and Apoptosis via the Phosphorylation of YAP in Hepatocellular Carcinoma. J Cancer. 2019; 10(12):2706-2719. PMC: 6584921. DOI: 10.7150/jca.31845. View

Morey L, Pascual G, Cozzuto L, Roma G, Wutz A, Benitah S . Nonoverlapping functions of the Polycomb group Cbx family of proteins in embryonic stem cells. Cell Stem Cell. 2012; 10(1):47-62. DOI: 10.1016/j.stem.2011.12.006. View

Huang Y, Liu L, Cai J, Yang L, Sun S, Zhao J . The Efficacy and Response Predictors of Platinum-Based Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer. Cancer Manag Res. 2020; 12:10469-10477. PMC: 7588671. DOI: 10.2147/CMAR.S270258. View

Su W, Han H, Wang Y, Zhang B, Zhou B, Cheng Y . The Polycomb Repressor Complex 1 Drives Double-Negative Prostate Cancer Metastasis by Coordinating Stemness and Immune Suppression. Cancer Cell. 2019; 36(2):139-155.e10. PMC: 7210785. DOI: 10.1016/j.ccell.2019.06.009. View

Zhao X, Wu X . Polycomb-group proteins in the initiation and progression of cancer. J Genet Genomics. 2021; 48(6):433-443. DOI: 10.1016/j.jgg.2021.03.013. View

Plys A, Davis C, Kim J, Rizki G, Keenen M, Marr S . Phase separation of Polycomb-repressive complex 1 is governed by a charged disordered region of CBX2. Genes Dev. 2019; 33(13-14):799-813. PMC: 6601514. DOI: 10.1101/gad.326488.119. View

10.

Zhang X, Wang C, Zhu C, Zhang J, Kan S, Du L . Overexpression of Bmi-1 in uterine cervical cancer: correlation with clinicopathology and prognosis. Int J Gynecol Cancer. 2011; 20(9):1597-603. View

11.

Cao L, Shen C, Zhu W . Histone modifications in DNA damage response. Sci China Life Sci. 2016; 59(3):257-70. DOI: 10.1007/s11427-016-5011-z. View

12.

Ali M, Strickfaden H, Lee B, Spyracopoulos L, Hendzel M . RYBP Is a K63-Ubiquitin-Chain-Binding Protein that Inhibits Homologous Recombination Repair. Cell Rep. 2018; 22(2):383-395. DOI: 10.1016/j.celrep.2017.12.047. View

13.

Hart D, Rodriguez Gutierrez D, Biason-Lauber A . CBX2 in DSD: The Quirky Kid on the Block. Sex Dev. 2022; 16(2-3):162-170. DOI: 10.1159/000522164. View

14.

Wheeler L, Watson Z, Qamar L, Yamamoto T, Post M, Berning A . CBX2 identified as driver of anoikis escape and dissemination in high grade serous ovarian cancer. Oncogenesis. 2018; 7(11):92. PMC: 6255906. DOI: 10.1038/s41389-018-0103-1. View

15.

Hu S, Yu L, Li Z, Shen Y, Wang J, Cai J . Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo. Cancer Biol Ther. 2010; 10(8):788-95. DOI: 10.4161/cbt.10.8.12913. View

16.

Bray F, Laversanne M, Sung H, Ferlay J, Siegel R, Soerjomataram I . Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3):229-263. DOI: 10.3322/caac.21834. View

17.

Ma Y, Liu L, Wei Z, Zhu M, Huang L, Wang S . Loss of CBX2 causes genomic instability and Wnt activation in high grade serous ovarian carcinoma cells. Mol Carcinog. 2023; 62(4):479-492. DOI: 10.1002/mc.23500. View

18.

Youmans D, Gooding A, Dowell R, Cech T . Competition between PRC2.1 and 2.2 subcomplexes regulates PRC2 chromatin occupancy in human stem cells. Mol Cell. 2020; 81(3):488-501.e9. PMC: 7867654. DOI: 10.1016/j.molcel.2020.11.044. View

19.

van Wijnen A, Bagheri L, Badreldin A, Larson A, Dudakovic A, Thaler R . Biological functions of chromobox (CBX) proteins in stem cell self-renewal, lineage-commitment, cancer and development. Bone. 2020; 143:115659. DOI: 10.1016/j.bone.2020.115659. View

20.

Bilton L, Warren C, Humphries R, Kalsi S, Waters E, Francis T . The Epigenetic Regulatory Protein CBX2 Promotes mTORC1 Signalling and Inhibits DREAM Complex Activity to Drive Breast Cancer Cell Growth. Cancers (Basel). 2022; 14(14). PMC: 9321755. DOI: 10.3390/cancers14143491. View